Damato Nicole Sells 23,814 Innovage Holding Shares in Routine Plan Trade Amid Volatile Market Conditions

Insider Selling in a Volatile Market

On September 25 2026, Chief Legal Officer Damato Nicole sold 23,814 shares of Innovage Holding Corp. (IHC) under a Rule 10b‑5‑1 plan at an average price of $8.70, leaving her with 304,897 shares. The transaction occurred just after the company’s March‑2026 public offering that saw ten million shares sold at $9.25 and a subsequent change in ownership structure. With the share price hovering near $8.90, Nicole’s sale represents a modest 7.8 % reduction of her holdings, but it is significant given the broader insider activity.

What Investors Should Watch

Nicole’s trade is part of a pattern of balanced buying and selling over the past year. In July 2026 she added 51,369 shares, and in August 2025 she sold 14,303 shares. The most recent sale—priced near the current market level—suggests she is not timing a “big‑wave” exit but is likely managing her personal liquidity or portfolio balance. In a period where the Nasdaq healthcare index is down 15 % and IHC’s 52‑week low sits at $3.94, the sale may be interpreted as a normal defensive maneuver rather than a signal of deteriorating fundamentals.

Implications for IHC’s Future

IHC’s price‑earnings ratio is an outlier at –440.75, reflecting negative earnings and a challenging operating environment. The company’s recent public offering and the infusion of capital from TCO Group Holdings are aimed at stabilizing cash flow and supporting expansion of its senior‑living and skilled‑nursing services. Nicole’s sale, while small relative to the total shares outstanding, could influence short‑term volatility, especially if her holdings were considered a “anchor” by the market. However, the continued presence of other top executives—CEO Blair Patrick, CFO Benjamin Adams—buying shares in July signals confidence in the company’s long‑term strategy.

Profile: Damato Nicole, Chief Legal Officer

Nicole’s insider history shows a disciplined approach: she alternates between buying during periods of lower valuation and selling when the price stabilizes near the offering level. Her largest single trade was a 19,401‑share sale in July 2026 at $11.58, a 30 % premium to the current price. She has maintained a cumulative holding of approximately 300,000 shares over the past 18 months, indicating a long‑term stake in the company’s health‑care portfolio. As the legal liaison between the board and regulatory bodies, Nicole’s trades are executed under pre‑approved 10b‑5‑1 plans, minimizing discretion and reducing market‑impact risk. Her trading pattern suggests she views IHC as a stable, long‑term investment rather than a speculative play.

Bottom Line

For investors, Nicole’s 23,814‑share sale is a routine, plan‑based transaction that should not materially alter the company’s ownership dynamics. It occurs against a backdrop of a sizable public offering, a change in indirect ownership structure, and a challenging earnings profile. The key takeaway is that IHC is actively managing its capital base while insiders continue to hold significant positions—an indicator that, despite short‑term volatility, the core leadership remains committed to the company’s strategic path.